Skip to content
  • Fact Sheet
  • Contact
  • Blog
  • English English
    • English English
    • Español Español
OligofastxOligofastx
  • ABOUT OLIGOFASTX
    • ABOUT OLIGOFASTX
      • About the project
      • Mission, Vision and Goals
      • Oligonucleotides
  • Rare diseases
    • Retinitis Pigmentosa
    • Leber Congenital Amaurosis
    • Cancer cachexia
    • Alström Syndrome
    • Fuchs’ corneal endothelial dystrophy
    • Guillain-Barré syndrome
    • Anaplastic thyroid cancer
  • TECHNOLOGIES
    • Design, Artificial Intelligence and Modelling
      • Artificial Intelligence
    • THERAPY DEVELOPMENT
      • sIRNA
      • Aptamer
      • Anti-miRNA
    • NANOTECHNOLOGY AND DRUG DELIVERY
      • Drug nanoliberation
      • Bioconjugates
    • PRODUCTION AND SCALING UP
      • Oligonucleotide scale-up and biosynthesis
  • Partner companies
    • Sylentis
    • aptaTargets
    • AptusBiotech
    • Arthex
    • Nanovex
    • Nostrum Biodiscovery
    • 53Biologics
  • Collaborators
  • Strategy

Blog

Artificial Intelligence applied to the diagnosis and treatment of rare diseases

That Artificial Intelligence is coming to our daily lives is nothing new. We have all [...]

30
Mar
Tribute to Severo Ochoa, the Spanish biochemist who received the Nobel Prize for discovering the enzymes involved in RNA synthesis.

Of Spanish origin, the small and idyllic town of Luarca (Asturias) was the birthplace of [...]

22
Mar
Spanish pharmaceutical industry, third largest exporter with 53% growth to 2022

We love to share good news from the sector. On this occasion, we share the [...]

14
Mar
#8M, #InternationalWomensDay: “For an inclusive digital world”

One more year, we celebrate #InternationalWomensDay: a day that not only commemorates and pays tribute [...]

08
Mar
Rare Disease Day

Oligofastx is a project born from a need: to offer a therapeutic pathway based on [...]

28
Feb
Metaverse opens new opportunities for research and collaboration

If there is one word that distinguishes OLIGOFASTX and its philosophy, it is innovation. Thanks [...]

20
Feb
The contribution of women in science

Since 2015, the International Day of Women and Girls in Science has been celebrated every [...]

13
Feb
World Cancer Day

As it could not be otherwise, from Oligofastx we join in the celebration of the [...]

03
Feb
Leber Congenital Amaurosis

Leber’s congenital amaurosis (LCA) is an eye disease that primarily affects the retina, the inner [...]

27
Jan
A 2023 with a hopeful look at therapeutic oligonucleotides

The last few years have been a true revolution in terms of discoveries and initiatives [...]

20
Jan
Cancer cachexia

Cancer cachexia is a complex metabolic syndrome characterized by marked loss of body weight, anorexia, [...]

16
Jan
Providing solutions for rare diseases: a priority for the UN

Perhaps the definition is not the most accurate, but in reality a rare disease does [...]

10
Jan
Goodbye 2022, welcome 2023

In the last days of the year, it is time to review everything we have [...]

28
Dec
Innovative and sustainable production of biological molecules

The Oligofastx project covers all areas, from start to finish, of the process of developing [...]

22
Dec
Personalized treatments for rare diseases with oligonucleotides pose universal challenges

There is no doubt that oligonucleotide therapies aimed at providing answers and improving the quality [...]

16
Dec
Oligonucleotides, the language of life in small doses

A technological revolution can start with a key concept, the application of an equation or, [...]

12
Dec
Solid-phase synthesis in the amplification and sequencing of nucleic acids

The Oligofastx project covers the different phases of the development of oligonucleotide-based therapies, from design [...]

28
Nov
Oligonucleotides for curing osteoporosis, premature aging in children and hepatitis B

OLIGOFASTX follows with great interest all the recent advances in the work with oligonucleotides, not [...]

25
Nov
Maurice Wilkins, the third man of the double helix

History is peppered with stories, legends and tales. And as in all of them, any [...]

07
Nov
Anaplastic thyroid cancer: the most aggressive and lethal type of cancer

Thyroid cancer is a common malignancy of the endocrine system. There are four types: Papillary [...]

26
Oct
Guillain-Barré Syndrome: when the immune system attacks peripheral nerves

Today we are going to talk about one of those diseases classified as rare, for [...]

20
Oct
The Most Excellent Nobel Laureates 2022: these were the winners in the categories of Chemistry and Medicine

The work of the most renowned scientists, artists and diplomats is rewarded every year at [...]

06
Oct
Retinitis pigmentosa, a genetic vision pathology

Every last Sunday of September is celebrated the International Retinitis Pigmentosa Day, one of the [...]

26
Sep
Steinert’s myotonic dystrophy: when muscles become unresponsive

Today is International Myotonic Dystrophy Day, a rare disease with no treatment or cure to [...]

15
Sep
The OLIGOFASTX project is born

The project, subsidised by the CDTI with 5.4 million euros and a final budget of [...]

21
Jul

About OLIGOFASTX

Comprehensive platform for the sustainable development of oligonucleotide-based therapies.

OLIGOFASTX is a multidisciplinary consortium led by Sylentis (PharmaMar Group) with the participation of six other Spanish companies: Nanovex Biotechnologies (Grupo Industrial Química del Nalón), Aptus Biotech, AptaTargets, Arthex Biotech, Nostrum Biodiscovery and 53Biologics.

Subsidised by the CDTI

Shortcuts

What is OLIGOFASTX
Rare diseases
Design, Modelling and Artificial Intelligence
Therapy development
Nanotechnology and drug delivery
Production and scaling
Partners
Collaborators
Strategy

partners

  • Fact Sheet
  • Legal Advice
  • Privacy Policy
  • Cookie Policy
  • Contact
Copyright 2023 © OLIGOFASTX
  • ABOUT OLIGOFASTX
    • ABOUT OLIGOFASTX
      • About the project
      • Mission, Vision and Goals
      • Oligonucleotides
  • Rare diseases
    • Retinitis Pigmentosa
    • Leber Congenital Amaurosis
    • Cancer cachexia
    • Alström Syndrome
    • Fuchs’ corneal endothelial dystrophy
    • Guillain-Barré syndrome
    • Anaplastic thyroid cancer
  • TECHNOLOGIES
    • Design, Artificial Intelligence and Modelling
      • Artificial Intelligence
    • THERAPY DEVELOPMENT
      • sIRNA
      • Aptamer
      • Anti-miRNA
    • NANOTECHNOLOGY AND DRUG DELIVERY
      • Drug nanoliberation
      • Bioconjugates
    • PRODUCTION AND SCALING UP
      • Oligonucleotide scale-up and biosynthesis
  • Partner companies
    • Sylentis
    • aptaTargets
    • AptusBiotech
    • Arthex
    • Nanovex
    • Nostrum Biodiscovery
    • 53Biologics
  • Collaborators
  • Strategy
  • English English
    • English English
    • Español Español
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}
  • English
  • Español